Leader in Prostate Cancer Imaging Prof. Frederik L. Giesel Joins Scientific Advisory Board
Melbourne (Australia) – 9 March 2020. Telix Pharmaceuticals Limited announces that Professor Dr. Frederik L. Giesel, MD, MBA has joined Telix’s Scientific Advisory Board.
Telix Pharmaceuticals Limited is pleased to announce that Professor Dr. Frederik L. Giesel, MD, MBA has joined Telix’s Scientific Advisory Board (SAB).
As a member of Telix’s Scientific Advisory Board, Prof. Giesel will advise Telix in relation to its R&D and clinical development activities spanning the Company’s prostate cancer, kidney cancer and glioblastoma (brain cancer) programs.
To read the full media release please click here.